Sort   by:  
 Page size 
UnknownNovel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial.
Not available
S-EPMC9397979 | biostudies-literature
UnknownEfficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Not available
S-EPMC5731244 | biostudies-literature
UnknownOsteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption.
Not available
S-EPMC7938889 | biostudies-literature
UnknownBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Not available
S-EPMC5819601 | biostudies-literature
UnknownBrainstem neurochemical profiles after hospitalisation for COVID-19: a 7T MR spectroscopy study.
Not available
S-EPMC12568683 | biostudies-literature
UnknownIntravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
Not available
S-EPMC7734592 | biostudies-literature
UnknownCohort profile: demographic and clinical characteristics of the MILESTONE longitudinal cohort of young people approaching the upper age limit of their child mental health care service in Europe.
Not available
S-EPMC8679118 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownChromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices.
Not available
S-EPMC8042019 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
Sort   by:  
 Page size